FINCAD Advances Buy Side Portfolio and Risk Solution
8.2.2018 14:00:00 EET | Business Wire | Press release
FINCAD, the leading provider of portfolio and risk analytics for multi-asset derivatives and fixed income, today announced advances to FINCAD F3, further enabling buy side firms to make superior investment and risk decisions.
Buy side investment managers face tough challenges to improve returns and reduce costs. To achieve these objectives, firms are using new asset classes, derivatives and emerging markets. However, inflexible legacy systems are often unable to handle these new demands. In addition, a patchwork of different systems is generally used for front office portfolio analytics and middle office risk. The critical downside to this approach is that the front and middle offices have inconsistent data, analytics and reports, requiring significant effort on daily reconciliations.
FINCAD F3 enables the buy side to meet their challenges with the best-in-class solution for enterprise portfolio and risk analytics, allowing firms to price and value virtually any instrument, consolidate disparate systems, and centralize data and analytics across the front and middle office. In addition, FINCAD F3 is ready to go with a standard set of pre-configured models and instruments, and is easily customized and integrated to existing data sources and applications. These powerful capabilities and swift implementations result in rapid ROI for clients.
A senior portfolio manager at a leading UK pension scheme said, “F3 is the most flexible valuation and risk analytics solution on the market. The ability to develop and implement highly tailored hedging strategies and produce intra-day risk has been extremely valuable.”
FINCAD’s innovations in portfolio and risk analytics have not gone unnoticed. FINCAD was recently named “Best Derivatives Valuation and Risk Solution” at The Hedge Fund Journal Awards 2018 , and experienced strong sales growth in 2017 with 17 F3 sales deals. New F3 clients in 2017 include leading hedge funds, asset managers, life insurers, regional banks and public sector lending institutions across North America, Europe and LATAM.
“Working closely with both our buy and sell side clients, we have built FINCAD F3 into a powerful portfolio and risk analytics solution for making better investment decisions” said Bob Park, FINCAD President and CEO. “Firms no longer need to choose between an off-the-shelf system with black box analytics or a customized solution that takes forever to implement. With FINCAD F3, firms don’t need to compromise. They get powerful out-of-the-box functionality, the flexibility for unlimited customization and are able to satisfy the competing demands of quants, portfolio managers, traders, risk managers and developers.”
FINCAD F3 is an enterprise portfolio and risk analytics solution that offers the built-in functionality and ease of use of off-the-shelf software, combined with unlimited flexibility to customize it to a firm’s specific trading style, business model and workflow. The enhanced FINCAD F3 solution offers users the following capabilities and benefits:
- Expand into more instruments and asset classes with a comprehensive library of industry standard tools and models. F3 provides unmatched flexibility for building custom curves and valuation models, and an unlimited ability to create tailored analytics with new Python MicroServices.
- Improve returns with the freedom to trade what, when and how you want—with no constraints, and make better portfolio and hedging decisions with accurate valuation and comprehensive risk reports in the intuitive F3 WorkStation application. Key reports include Greeks, Sensitivities, What-if analysis, Cash flows, Mark-to-market and P&L attribution.
- Improve risk management with a complete view of performance and risk across the firm with a comprehensive set of intra-day risk reports that can be easily customized. Key reports include VaR, Expected Shortfall, Stress testing and Scenario analysis.
- Achieve rapid ROI with fast implementations and scalable technology that can be deployed on premise or in the cloud. Integrate to existing data sources and systems with powerful APIs, and use multiple front end applications including F3 WorkStation, Microsoft Excel, or an in-house application. Market data, reference data, analytics definitions and derived data are all stored in a managed database, with versioning and a full audit trail.
About FINCAD
FINCAD is the leading provider of enterprise portfolio and risk analytics for multi-asset derivatives and fixed income. An industry standard since 1990, our advanced analytics, flexible architecture and patented technology enable financial institutions to make better investment and risk decisions. Our goal is to provide our clients with solutions that help them achieve their goals, with no compromises. Clients include leading global asset managers, hedge funds, insurance companies, pension funds, banks and auditors. For more information, visit www.fincad.com.
Follow Us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180208005176/en/
Contact information
FINCAD
Rob Garfield, +1-646-217-4572
r.garfield@fincad.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease2.5.2026 00:28:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 19:08:00 EEST | Press release
A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom